# MAINTOBA INFLUENZA STUDY

> **NIH NIH R01** · UNIVERSITY OF VIRGINIA · 1991 · $157,977

## Abstract

Influenza continues to cause significant morbidity and mortality.  In spite
of strong recommendations from expert advisory groups, influenza vaccine is
not widely used.  Reasons for this include (1) difficulty in identifying
high-risk patients; (2) uncertainty about the long-term health benefits to
patients who are vaccinated.  Also, little is known about patterns of use
of influenza vaccine.

The Manitoba Influenza Study will address each of these questions.  This
four-year project will use a person-oriented linked record derived from
claims data gathered by the Manitoba Health Services Commission (MHSC) for
the period 1980-86.  The linked record includes demographic data on MHSC
enrollees and physicians, influenza vaccinations.  Two influenza outbreak
periods (1982-83 and 1985-86) will be studied.  Five studies will be
undertaken:  Study 1 will examine the natural history of high-risk
conditions to identify factors associated with increased risk of ambulatory
care visits, hospitalization, and death due to respiratory conditions
during outbreak periods.  It will also identify missed opportunities for
vaccination.  Study 2 will use both retrospective cohort and case-control
methods to assess the clinical effectiveness of influenza vaccination in
preventing influenza-related ambulatory care visits, hospitalizations, and
deaths.  Study 3 patient receipt of vaccine.  Study 4 will assess known and
hitherto unknown adverse effects of influenza vaccination serious enough to
require medical care within 3, 7, 14 and 28 days of vaccination.  Study 5
will assess the long-term (five-year) outcomes of patients who have had and
have not had hospital care for influenza-related illness to determine
whether of not "pneumonia is the old man's friend".

The Manitoba Influenza Study will provide new information on the clinical
effectiveness of influenza vaccination, its safety, and its long-term
health benefits.  It will characterize patterns of vaccine use and suggest
new policies and strategies for influenza vaccination for both the United
States and Canada.

## Key facts

- **NIH application ID:** 3120922
- **Project number:** 5R01AG009145-02
- **Recipient organization:** UNIVERSITY OF VIRGINIA
- **SAM.gov UEI:** JJG6HU8PA4S5
- **Principal Investigator:** DAVID S. FEDSON
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1991
- **Award amount:** $157,977
- **Award type:** 5
- **Project period:** 1990-03-07 → 1993-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3120922

## Citation

> US National Institutes of Health, RePORTER application 3120922, MAINTOBA INFLUENZA STUDY (5R01AG009145-02). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3120922. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*